Loading
A phase 1/2 trial of AK117, Carboplatin, Cisplatin and Gemcitabine in advanced solid tumours, run by Akeso, active and no longer recruiting.
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05229497 by Akeso, with 154 participants enrolled, started 2022-05-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil and Gemcitabine.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Gemcitabine, Cisplatin and the tag pipeline.